pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›KEYTRUDA QLEX
drug
save

KEYTRUDA QLEX

updated 6mo ago
by Merck Sharp & Dohme LLC
community read0 votes

🐶 often sniffed alongside

top 8
  • drugpembrolizumab269 co-mentions · 131 sources
  • drugKEYTRUDA269 co-mentions · 131 sources
  • tagApproval266 co-mentions · 128 sources
  • drugCancer Program133 co-mentions · 128 sources
  • drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
  • tagGlioblastoma2 co-mentions · 1 sources
  • tagOncology1 co-mentions · 1 sources
  • tagNeurology1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying KEYTRUDA QLEX

  • phase2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumorsrecruitingn=392
  • phase2ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiationrecruitingn=34
  • phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).recruitingn=605
  • phase3A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)recruitingn=750
  • phase2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)recruitingn=160
  • phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studiesrecruitingn=170
  • phase2A Study of DS-3939a in Participants With Solid Tumorsrecruitingn=400
  • phase3A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgeryactive not recruitingn=1,564

News(10)

  • Keytruda biosimilars are coming — but they face an uphill battle
    A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
    biopharma_dive · 14d ago
  • Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
    On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertensi…
    biospace · 18d ago
  • Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
    Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…
    fiercebiotech · 19d ago
  • Opinion: Cancer vaccines are finally here. How do we get them to patients?
    “If we want cancer vaccines to reach patients faster than BRCA testing did, there are several challenges to address now,” write Karen E. Knudsen and Othman Laraki.
    stat · 21d ago
  • ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
    After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last w…
    biospace · 21d ago
  • ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
    Merck & Co. and Moderna always knew they would make headlines in Madrid this week—just not in the way it happened.
    fiercebiotech · 24d ago
  • Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
    Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
    biospace · 1mo ago
  • Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
    A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
    biopharma_dive · 1mo ago
  • The signal that changes everything: understanding MRD in oncology drug development
    Is the cancer truly gone?
    fiercebiotech · 2mo ago
  • Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
    Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
    biospace · 2mo ago
view all news mentions →
brand
KEYTRUDA QLEX
generic
PEMBROLIZUMAB
Data sources
ClinicalTrials.gov
last refreshed 24m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?